TAG:
FDA
FDA Has Future Avenues to LDT Oversight
By Scott Wallask | From the Volume XXXII, No. 15 – October 27, 2025 Issue
CEO SUMMARY: Even though a federal court vacated the FDA’s final rule for laboratory developed tests, experts warn that the agency may still be able to regulate some LDTs via its authority over diagnostic software. An attorney notes that software’s central role in mode…
Lumea’s Digital Pathology Success Lands It on Inc. 5000
By Scott Wallask | From the Volume XXXII, No. 14 – October 6, 2025 Issue
Digital pathology company Lumea was perhaps the most notable entry from the clinical laboratory world to make it onto the Inc. 5000 list of the fastest growing private companies in America in 2025. Lumea placed mid-pack at No. 2,468 …
AI Hype in Labs: 6 Tips to Sniff Out the BS
By Scott Wallask | From the Volume XXXII, No. 11 – August 4, 2025 Issue
CEO SUMMARY: In the final entry of our artificial intelligence series, the co-founders of Sample Healthcare discuss how clinical labs can evaluate AI vendors effectively, with an emphasis on assessing technical credentials and quick proofs of concept. Armed with the right …
At ADLM 2025, Spotlight Shines on Relationships
By Scott Wallask | From the Volume XXXII, No. 11 – August 4, 2025 Issue
CEO SUMMARY: At the ADLM conference, a new industry survey about the dynamic relationship between medical laboratories, physicians, and patients presented a strong argument for labs taking the lead in communicating and being more accessible to their colleagues. A troubleso…
JAMA Authors Warn LDT Legal Defeat Brings Risk for Labs
By Scott Wallask | From the Volume XXXII, No. 11 – August 4, 2025 Issue
CLINICAL LABORATORY AND ANATOMIC PATHOLOGY LEADERS WILL WANT TO NOTE will a recent JAMA Health Forum article that strikes a cautionary tone about the future of laboratory developed test (LDT) regulation. The piece argued that the recent federal court decision…
Fast, $17.5B Deal Lands Waters Corp. in IVD Market
By Janette Wider | From the Volume XXXII, No. 11 – August 4, 2025 Issue
WHEN BECTON DICKINSON (BD) ANNOUNCED ITS INTENT to spin off its in vitro diagnostics (IVD) and life sciences units in February, few observers expected a deal to close just five months later. But now that such an agreement has occurred as of July 14, the buy…
For AI Regulation, Look to Data Laws, FDA Action
By Scott Wallask | From the Volume XXXII, No. 10 – July 14, 2025 Issue
CEO SUMMARY: AI is creating legal uncertainty for clinical labs, especially around data privacy and FDA oversight of AI tools in diagnostics. Few court cases exist yet that interpret AI use within clinical settings, but labs must watch how HIPAA and state laws wield influence. Vendor soft…
Lab Industry Fallout from CLIAC Termination
By Stephen Beale | From the Volume XXXII, No. 9 – June 23, 2025 Issue
CEO SUMMARY: Some diagnostic lab leaders and anatomic pathology practice owners may not immediately think that the elimination of a federal advisory panel should be on their radar. But the demise of the Clinical Laboratory Improvement Advisory Committee may cost labs by de…
June 23, 2025, Intelligence: Late-Breaking Lab News
By Scott Wallask | From the Volume XXXII, No. 9 – June 23, 2025 Issue
Clinical labs that have business in clinical trials involving genetic samples should note that on June 18, the Food and Drug Administration (FDA) ordered a review of new trials that send samples to “hostile countries for genetic engineering.” The FDA mentioned China specifically. Th…
June 2, 2025, Intelligence: Late-Breaking Lab News
By Scott Wallask | From the Volume XXXII, No. 8 – June 2, 2025 Issue
Our sibling publication, G2 Intelligence, reported in May about a new Department of Justice (DOJ) memorandum that indicated prosecutors will seek to exercise fairness when deciding how to pursue fraud cases against clinical laboratories and other organizations. The DOJ emphasiz…
CURRENT ISSUE
Volume XXXII, No. 15 – October 27, 2025
The Dark Report examines the momentous decision by the VA to switch accreditors from The Joint Commission to CAP. Also, we analyze retractions in pathology journals to gain insight into scientific fraud.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized
The Dark Report
1000 N West Street, Suite 1200 Wilmington, Delaware, United States, 19801
Phone: 512-264-7103
Email: info@darkreport.com
© 2025 The Dark Report. All rights reserved. Part of the LabX Media Group